Udenafil

For research use only. Not for therapeutic Use.

  • CAT Number: I002920
  • CAS Number: 268203-93-6
  • Molecular Formula: C25H36N6O4S
  • Molecular Weight: 516.66
  • Purity: ≥95%
Inquiry Now

Udenafil (CAT: I002920), also known as DA8159, is a selective phosphodiesterase 5 (PDE5) inhibitor primarily used in urology to treat erectile dysfunction (ED). PDE5 is an enzyme that regulates the degradation of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the penile region. By inhibiting PDE5, udenafil increases cGMP levels, leading to smooth muscle relaxation, vasodilation, and improved blood flow to the erectile tissue, facilitating penile erection. Udenafil belongs to the same class of medications as sildenafil (Viagra) and tadalafil (Cialis) and is considered an effective option for the management of ED.


Catalog Number I002920
CAS Number 268203-93-6
Synonyms

3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-propoxybenzenesulfonamide

Molecular Formula C25H36N6O4S
Purity ≥95%
Target PDE
Solubility DMSO: ≥ 33 mg/mL
Storage Store at -20C
Reference

</br>1:A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction. Moon KH, Kim SW, Moon du G, Kim JJ, Park NC, Lee SW, Paick JS, Ahn TY, Chung WS, Min KS, Park JK, Yang DY, Shin HS, Park K.J Sex Med. 2016 Aug;13(8):1263-9. doi: 10.1016/j.jsxm.2016.05.011. Epub 2016 Jun 17. PMID: 27319276 </br>2:Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment. Kim A, Lee J, Shin D, Jung YJ, Bahng MY, Cho JY, Jang IJ.Br J Clin Pharmacol. 2016 Aug;82(2):389-98. doi: 10.1111/bcp.12977. Epub 2016 Jun 3. PMID: 27084997 </br>3:The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. Choi HK, Jung JA, Shon J, Bahng MY, Cho DY, Yeo CW, Kim EY, Shin JG.J Clin Pharmacol. 2016 Nov;56(11):1372-1377. doi: 10.1002/jcph.739. PMID: 27006150 </br>4:Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy. Kim TH, Ha YS, Choi SH, Yoo ES, Kim BW, Yun SJ, Kim WJ, Kwon YS, Kwon TG.Int J Impot Res. 2016 Mar-Apr;28(2):80. doi: 10.1038/ijir.2016.9. No abstract available. PMID: 26965160 </br>5:The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis. Irkilata L, Aydin HR, Ozer I, Aydin M, Demirel HC, Moral C, Atilla MK.Ren Fail. 2016;38(3):357-61. doi: 10.3109/0886022X.2015.1128840. Epub 2016 Jan 4. PMID: 26727286 </br>6:Protective effects of udenafil citrate, piracetam and dexmedetomidine treatment on testicular torsion/detorsion-induced ischaemia/reperfusion injury in rats. Tuglu D, Yuvanc E, Ozan T, Bal F, Yilmaz E, Atasoy P, Kisa U, Batislam E.Andrologia. 2016 Aug;48(6):676-82. doi: 10.1111/and.12499. Epub 2015 Nov 20. PMID: 26589469 </br>7:Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy. Kim TH, Ha YS, Choi SH, Yoo ES, Kim BW, Yun SJ, Kim WJ, Kwon YS, Kwon TG.Int J Impot Res. 2016 Jan-Feb;28(1):25-30. doi: 10.1038/ijir.2015.28. Epub 2015 Oct 29. Erratum in: Int J Impot Res. 2016 Mar-Apr;28(2):80. PMID: 26510966 </br>8:Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study. Lee TY, Choi JS, Oh HC, Song TJ, Do JH, Cheon YK.Korean J Intern Med. 2015 Sep;30(5):602-9. doi: 10.3904/kjim.2015.30.5.602. Epub 2015 Aug 27. PMID: 26354054 Free PMC Article</br>9:Re: Efficacy of Once-Daily Administration of Udenafil for 24 Weeks on Erectile Dysfunction: Results from a Randomized Multicenter Placebo-Controlled Clinical Trial. Seftel AD.J Urol. 2015 Aug;194(2):495. doi: 10.1016/j.juro.2015.05.063. Epub 2015 May 18. No abstract available. PMID: 26195408 </br>10:PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial. Kim KH, Kim HK, Hwang IC, Cho HJ, Je N, Kwon OM, Choi SJ, Lee SP, Kim YJ, Sohn DW.Am Heart J. 2015 Jun;169(6):813-822.e3. doi: 10.1016/j.ahj.2015.03.018. Epub 2015 Apr 1. PMID: 26027619

Request a Quote